Want to see SE:CARA full AI Analyst Report?
CARA Stock Chart & Stats
kr29.00
-kr0.28(-1.22%)
At close: 4:00 PM EST
kr29.00
-kr0.28(-1.22%)
Day’s Range― - ―
52-Week Rangekr21.70 - kr30.55
Previous CloseN/A
Volume42.56K
Average Volume (3M)175.33K
Market Cap
kr1.52B
Enterprise Valuekr1.45B
Total Cash (Recent Filing)kr51.43M
Total Debt (Recent Filing)kr28.66M
Price to Earnings (P/E)42.1
Beta0.07
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding70,324,780
10 Day Avg. Volume229,351
30 Day Avg. Volume175,329
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)2.36
Price to Sales (P/S)5.54
P/FCF Ratio-4.00K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.45
Revenue Forecast (FY)kr410.33M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained very strong top-line growth (TTM ~200%) signals expanding adoption of the company's healthcare software and successful go-to-market execution. Over a 2–6 month horizon this growth supports scale economics, recurring revenue visibility, and provides room to invest in product and sales to deepen market penetration.
High Gross MarginsConsistently very high gross margins (~81–85%) reflect strong unit economics and pricing power typical of software businesses. These margins create structural operating leverage: as revenue scales, incremental revenue can flow to the bottom line if operating costs are controlled, supporting sustainable profitability over time.
Conservative Balance SheetA low-debt balance sheet reduces solvency and refinancing risk and gives management flexibility to fund product development, M&A, or absorb earnings volatility. For a company with uneven cash flow history, low leverage materially strengthens resilience and supports multi-month strategic initiatives without urgent financing.
Bears Say
Volatile ProfitabilityWide swings in operating performance—losses in 2023–2024, profit in 2025, then renewed pressure in the TTM—indicate the company has not yet established durable operating margins. This variability raises execution risk and complicates forecasting, making sustained conversion of high gross profit into net earnings uncertain.
Uneven Cash GenerationHistorically inconsistent operating and free cash flow—including deeply negative free cash flow in 2023—means cash generation is not yet reliably aligned with reported earnings. Persistent variability in cash conversion can constrain reinvestment, limit margin improvement plans, and increase the likelihood of future financing needs.
Weak Return MetricsDespite a sizable equity base, negative ROE in loss years and slightly negative ROE in the TTM show the company has not consistently converted capital into shareholder returns. Continued weak returns imply inefficiencies or margin shortfalls that, if persistent, will limit long-term shareholder value creation.
Carasent AB News
CARA FAQ
What was Carasent AB’s price range in the past 12 months?
Carasent AB lowest stock price was kr21.70 and its highest was kr30.55 in the past 12 months.
What is Carasent AB’s market cap?
Carasent AB’s market cap is kr1.52B.
When is Carasent AB’s upcoming earnings report date?
Carasent AB’s upcoming earnings report date is Oct 15, 2026 which is in 96 days.
How were Carasent AB’s earnings last quarter?
Carasent AB released its earnings results on Jul 10, 2026. The company reported -kr0.041 earnings per share for the quarter, missing the consensus estimate of kr0.02 by -kr0.061.
Is Carasent AB overvalued?
According to Wall Street analysts Carasent AB’s price is currently Overvalued.
Does Carasent AB pay dividends?
Carasent AB pays a Notavailable dividend of kr1.84 which represents an annual dividend yield of N/A. See more information on Carasent AB dividends here
What is Carasent AB’s EPS estimate?
Carasent AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Carasent AB have?
Carasent AB has 70,324,780 shares outstanding.
What happened to Carasent AB’s price movement after its last earnings report?
Carasent AB reported an EPS of -kr0.041 in its last earnings report, missing expectations of kr0.02. Following the earnings report the stock price went up 7.253%.
Which hedge fund is a major shareholder of Carasent AB?
Currently, no hedge funds are holding shares in SE:CARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden.
Technical Analysis
EQL Pharma AB
―
Vicore Pharma Holding AB
―
Humana AB
―
Xspray Pharma AB
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---